+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Scynexis Inc - logo

SCYNEXIS is a drug development company that develops and commercializes anti-infectives to address unmet therapeutic needs. Its lead product candidate, SCY-078, is a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Founded in 1999, the company is headquartered in Jersey City, New Jersey.

From
From
Allergic Bronchopulmonary Aspergillosis - Pipeline Insight, 2020 - Product Thumbnail Image

Allergic Bronchopulmonary Aspergillosis - Pipeline Insight, 2020

  • Clinical Trials
  • February 2020
  • 106 Pages
  • Global
From
From
From
From
Antifungal Drugs: Global Strategic Business Report - Product Thumbnail Image

Antifungal Drugs: Global Strategic Business Report

  • Report
  • December 2023
  • 179 Pages
  • Global
From
Antifungal Drugs: Technologies and Global Markets 2021-2026 - Product Thumbnail Image

Antifungal Drugs: Technologies and Global Markets 2021-2026

  • Report
  • November 2021
  • 295 Pages
  • Global
From
Hepatitis B - Pipeline Review, H2 2020 - Product Thumbnail Image

Hepatitis B - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 575 Pages
  • Global
From
From
Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021 - Product Thumbnail Image

Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 86 Pages
  • Global
From
From
Global Antifungal Drugs Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Antifungal Drugs Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Loading Indicator